833 related articles for article (PubMed ID: 28445811)
1. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Jojima T; Uchida K; Akimoto K; Tomotsune T; Yanagi K; Iijima T; Suzuki K; Kasai K; Aso Y
Atherosclerosis; 2017 Jun; 261():44-51. PubMed ID: 28445811
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-(1-7) regulates angiotensin II-induced matrix metalloproteinase-8 in vascular smooth muscle cells.
Zhang F; Li S; Song J; Liu J; Cui Y; Chen H
Atherosclerosis; 2017 Jun; 261():90-98. PubMed ID: 28283184
[TBL] [Abstract][Full Text] [Related]
3. Tryptanthrin Regulates Vascular Smooth Muscle Cell Phenotypic Switching in Atherosclerosis by AMP-Activated Protein Kinase/Acetyl-CoA Carboxylase Signaling Pathway.
Shi X; Zhang Y; Han J; Peng W; Fang Z; Qin Y; Xu X; Lin J; Xiao F; Zhao L; Lin Y
J Cardiovasc Pharmacol; 2021 May; 77(5):642-649. PubMed ID: 33951699
[TBL] [Abstract][Full Text] [Related]
4. PINK1/Parkin-mediated mitophagy promotes apelin-13-induced vascular smooth muscle cell proliferation by AMPKα and exacerbates atherosclerotic lesions.
He L; Zhou Q; Huang Z; Xu J; Zhou H; Lv D; Lu L; Huang S; Tang M; Zhong J; Chen JX; Luo X; Li L; Chen L
J Cell Physiol; 2019 Jun; 234(6):8668-8682. PubMed ID: 30456860
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.
Shi L; Ji Y; Jiang X; Zhou L; Xu Y; Li Y; Jiang W; Meng P; Liu X
Cardiovasc Diabetol; 2015 Feb; 14():18. PubMed ID: 25855361
[TBL] [Abstract][Full Text] [Related]
6. Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress.
Yang G; Lei Y; Inoue A; Piao L; Hu L; Jiang H; Sasaki T; Wu H; Xu W; Yu C; Zhao G; Ogasawara S; Okumura K; Kuzuya M; Cheng XW
Atherosclerosis; 2017 Sep; 264():1-10. PubMed ID: 28734203
[TBL] [Abstract][Full Text] [Related]
7. Gliclazide, a K
Lee KY; Kim JR; Choi HC
Vascul Pharmacol; 2018 Mar; 102():21-28. PubMed ID: 29337033
[TBL] [Abstract][Full Text] [Related]
8. SHP2 inhibitor PHPS1 protects against atherosclerosis by inhibiting smooth muscle cell proliferation.
Chen J; Cao Z; Guan J
BMC Cardiovasc Disord; 2018 Apr; 18(1):72. PubMed ID: 29703160
[TBL] [Abstract][Full Text] [Related]
9. Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms.
Koshibu M; Mori Y; Saito T; Kushima H; Hiromura M; Terasaki M; Takada M; Fukui T; Hirano T
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E895-E907. PubMed ID: 30860874
[TBL] [Abstract][Full Text] [Related]
10. Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway.
Sung JY; Choi HC
Vascul Pharmacol; 2012; 56(1-2):1-8. PubMed ID: 21708289
[TBL] [Abstract][Full Text] [Related]
11. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation.
Nagata D; Takeda R; Sata M; Satonaka H; Suzuki E; Nagano T; Hirata Y
Circulation; 2004 Jul; 110(4):444-51. PubMed ID: 15262850
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways.
Nagayama K; Kyotani Y; Zhao J; Ito S; Ozawa K; Bolstad FA; Yoshizumi M
PLoS One; 2015; 10(9):e0137960. PubMed ID: 26379274
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone Inhibits Angiotensin II-Induced Proliferation and Migration of Vascular Smooth Muscle Cells Through the AMPK/PPARγ/PGC-1α Pathway.
Pei X; Li X; Chen H; Han Y; Fan Y
DNA Cell Biol; 2016 Aug; 35(8):426-33. PubMed ID: 27064837
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway.
Zhao L; Li AQ; Zhou TF; Zhang MQ; Qin XM
Am J Physiol Cell Physiol; 2014 Dec; 307(12):C1130-41. PubMed ID: 25298426
[TBL] [Abstract][Full Text] [Related]
15. Arginase-II induces vascular smooth muscle cell senescence and apoptosis through p66Shc and p53 independently of its l-arginine ureahydrolase activity: implications for atherosclerotic plaque vulnerability.
Xiong Y; Yu Y; Montani JP; Yang Z; Ming XF
J Am Heart Assoc; 2013 Jul; 2(4):e000096. PubMed ID: 23832324
[TBL] [Abstract][Full Text] [Related]
16. AMP-activated protein kinase inhibits transforming growth factor-β-mediated vascular smooth muscle cell growth: implications for a Smad-3-dependent mechanism.
Stone JD; Holt AW; Vuncannon JR; Brault JJ; Tulis DA
Am J Physiol Heart Circ Physiol; 2015 Oct; 309(8):H1251-9. PubMed ID: 26276823
[TBL] [Abstract][Full Text] [Related]
17. Zedoarondiol Inhibits Platelet-Derived Growth Factor-Induced Vascular Smooth Muscle Cells Proliferation via Regulating AMP-Activated Protein Kinase Signaling Pathway.
Mao H; Tao T; Song D; Liu M; Wang X; Liu X; Shi D
Cell Physiol Biochem; 2016; 40(6):1506-1520. PubMed ID: 27997894
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification.
Lee J; Hong SW; Kim MJ; Moon SJ; Kwon H; Park SE; Rhee EJ; Lee WY
Diabetes Metab J; 2024 Jan; 48(1):83-96. PubMed ID: 38173373
[TBL] [Abstract][Full Text] [Related]
19. Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation.
Sahara M; Ikutomi M; Morita T; Minami Y; Nakajima T; Hirata Y; Nagai R; Sata M
Cardiovasc Res; 2014 Feb; 101(2):236-46. PubMed ID: 24193738
[TBL] [Abstract][Full Text] [Related]
20. Potent Vasoconstrictor Kisspeptin-10 Induces Atherosclerotic Plaque Progression and Instability: Reversal by its Receptor GPR54 Antagonist.
Sato K; Shirai R; Hontani M; Shinooka R; Hasegawa A; Kichise T; Yamashita T; Yoshizawa H; Watanabe R; Matsuyama TA; Ishibashi-Ueda H; Koba S; Kobayashi Y; Hirano T; Watanabe T
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
